When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
In Q2/2019, Hepion Pharmaceuticals (HEPA) started a “new clinical life” with a name change from ContraVir Pharmaceuticals (CTRV). It also streamlined its clinical program with a focus on CRV431 in NASH and Hepatitis B infection. The timeline revealed by the company showed that the Phase 2 safety and efficacy study of CRV431 in NASH will be initiated at the earliest Q4/2020 (Fig. 1).
Fig. 1: Proposed timeline of events for the clinical development of CRV431 for NASH
Between now and then, HEPA will undertake preclinical and toxicology/carcinogenicity studies as is required